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Information regarding the most pertinent side effects were 
collected, as well as the perceived utility of the aid.  
Results: Thirty-two participants (16 men, 16 women) with a 
median age of 34.5 (range 18-64) enrolled in this study. Twenty-
six subjects (81%) selected TORS as their preferred treatment 
option. Tradeoff revealed that participants were willing to 
accept a median score of 10% (range 5-50) decrease in survival 
to maintain their treatment choice. Regarding side effect 
profiles, the most concerning risks of TORS were: bleeding, 
death, stroke and aspiration pneumonia. Whereas, the most 
concerning toxicities of RT were: tooth decay, need of a feeding 
tube, and the risk of secondary malignancy. Finally, all subjects 
indicated that if they would value having a similar tool available 
perchance they are in a similar situation. 
Conclusions: A novel web-based Decision Aid has been developed 
for patients with early oropharyngeal cancer. The finding that 
TORS was preferred over RT in a sample of healthy volunteers 
necessitates confirmation in a cohort of patients with early 
oropharyngeal cancer. This tool holds promise in the era of 
shared-decision making and personalized patient-centred care. 
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Purpose: The objectives of this study are to (1) quantify 
intrafraction motion (IFM) during lung volumetric-modulated arc 
therapy (VMAT) and (2) evaluate the impact of mid-treatment 
patient repositioning after cone beam computed tomography 
(CBCT) acquisition upon target coverage. 
Methods and Materials: This analysis included lung tumours 
treated with VMAT between April 2012 and June 2015 with 50-60 
Gy in 3-5 fractions. Treatment planning consisted of a four-
dimensional (4D) CT scan from which an internal target volume 
(ITV) delineation was performed. A 5 mm margin was added in 
all directions to obtain the final planning target volume (PTV). 
Treatment sessions were performed in supine position with a 
customized dual vacuum immobilization device (BodyFIX, Elekta, 
Stockholm, Sweden). All patients underwent pre and mid-
treatment CBCTs to ensure proper repositioning. Following each 
CBCT, a two-step rigid registration was performed by an 
experienced radiation oncologist according to the planning CT, 
taking into account organs at risk (OARs). Bone shift was first 
assessed with a registration of the vertebrae adjacent to the 
lesion. Then, tumour shift was isolated with a soft tissue 
registration by aligning targets. IFM, combining bone and tumour 
shifts, was defined as the target displacement from pre to mid-
treatment CBCT acquisition and was quantified in terms of 
anterior-posterior (AP), cranio-caudal (CC) and medio-lateral 
(ML) amplitudes as well as three-dimensional (3D) vector. For 
patients with IFM ≥ 5 mm, a post-hoc dose calculation analysis 
was performed to assess target coverage impacts of mid-
treatment CBCT-guided repositioning. 
Results: Ninety-seven patients, totalizing 367 fractions, were 
included. Mean (±SD) overall treatment time was 53:02 ± 13:08 
min. Mean time from pre to mid-treatment CBCT acquisition was 
22:58 ± 5:33 min. Mean time to perform mid treatment CBCT 
scan acquisition, registrations and couch repositioning was 15:49 
± 4:14 min. Mean IFM amplitudes were 0.9 ± 1.2 mm, 0.6 ± 1.0 
mm and 0.6 ± 0.8 mm in the AP, CC and ML respectively. IFM was 
< 3 mm and < 5 mm in all directions in respectively 315/367 (86%) 
and 358/367 (98%) fractions. Mean 3D IFM vector was 1.5 ± 1.4 
mm (max = 8.1 mm) and was < 5 mm in 354/367 (96%). Among 
the 13 fractions with IFM vector ≥ 5 mm, 11/13 (85%) were 
dominantly induced by a tumour shift. For all these fractions, 
dose calculation analysis of worst-case scenario indicates that 
ITV coverage would have remained ≥ 95% without mid-treatment 
CBCT-guided patient repositioning. 
Conclusions: For 96% of fractions in patients immobilized with a 
customized BodyFIX dual vacuum bag, the IFM vector was within 
the 5 mm PTV margin used. Mid-treatment CBCT-guided couch 
repositioning did not significantly impact ITV coverage and 
prolonged treatment duration. Mid-treatment imaging may 
remain pertinent for selected patients with strict OAR dose 
constraints. 
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Purpose: Chest wall (CW) pain is as a possible late toxicity after 
SBRT. Several dosimetric factors have been reported to predict 
it, however, with no clear validation. This article reports our 
institutional experience with CW pain and the search for dose 
constraints for the CW as organ at risk in a homogeneous group 
of patients treated with the same dose and fractionation, 
planned with heterogeneity correction, without any initial dose 
constraint to the CW at the initial planning. 
Material and Methods: Patients with localized lung tumours, 
treated with SBRT the way mentioned above, to a dose of 48 Gy 
in 3 fractions, with the PTV touching the CW were reviewed. CW 
(2 cm expansion) was contoured retrospectively. Using Eclipse 
(Varian) software, common metrics of the absolute volume of the 
CW receiving 30 Gy or more (V30Gy), the intersecting volumes 
(in cm3) between the PTV and CW volumes, the mean dose and 
the max dose of the CW volume were extracted. CW pain was 
graduated by Common Terminology Criteria for Adverse Events 
v3.0. Data analysis and data correlation was carried out using the 
widely used Dose Response Explorer System1 (DREES) software, 
which allows for analytical and data-driven outcome modeling. 
Results: Seventy-five lung lesions in 71 patients met the criteria 
for our study. After a median follow up of 16 months, five 
patients reported CW pain (3 Grade = 3 and 2 Grade = 2). Median 
time for CW pain to manifest was seven months. The median 
volume of CW receiving > 30 Gy was 26 cc (range: 0.1 – 126 cc). 
The V30 Gy volumes (cm3) of the five cases with CW pain were 
15, 15, 20, 47 and 100. For all lesions, mean Dose to CW = 54.2 
± 2.3 Gy. Median max CW dose = 57 Gy. After DREES analysis, no 
correlation between the variables studied and CW pain was 
found. 
Conclusions: CW pain is an important late toxicity after SBRT in 
lung tumours. V30 Gy of the CW has been often used to decrease 
the risk of CW pain, but the volume is not clear. None of the 
common variables (including V30 Gy) analyzed in this study was 
statistically significant for CW pain. Good dosimetric constraints 
to decrease risk of CW pain remain to be determined.  
(1) El Naqa I, et al. Dose response explorer: an integrated open-
source tool for exploring and modelling radiotherapy dose-
volume outcome relationships. Physics in Medicine and Biology 
2006. 
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Purpose: To assess the intra-fraction tumour stability of lung 
cancer patients treated by cone beam computed tomography-
guided (CBCT) stereotactic body radiotherapy (SBRT) without 
any frame or immobilization devices. 
Materials and Methods: Localized lung cancer patients were 
treated with SBRT, positioned supine, with arms held above the 
head, a foam support under the knees and without any further 
immobilization. Internal target volume (ITV) was generated from 
4D-CT simulation around which a 5 mm symmetric PTV margin 
was added. All patients (except one) received 48 Gy in 3 
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fractions. Treatments were planned on Eclipse software (Varian 
Medical Systems, Inc) using 7-9 static fields or two volumetric 
modulated arcs for delivery on Varian linacs. Kilovoltage free 
breathing CBCTs were taken both for initial patient positioning 
and also immediately after treatment. The pre- and post-
treatment CBCTs were compared to confirm that the lung tumour 
remained inside the PTV and to assess the stability and the 
suitability of the PTV margin used. Comparisons were performed 
using a visual match by at least two experienced professionals in 
Varian’s Offline Review software. The time interval between 
both CBCTs was extracted trying to have a measure of the 
treatment time. 
Results: There were 44 cases/treatments with pre- and post-
treatment CBCTs reviewed. The mean time between the CBCTs 
(treatment time) was 16.5 ± 6 minutes (range: 10 to 34 minutes). 
In all cases the tumour was appropriately kept inside the PTV in 
the post-treatment CBCT. The mean corrections between pre 
and post-treatment CBCTs were -0.7 ± 1.6 mm (range -5.0 to 3.0 
mm) vertically, -0.3 ± 1.7 mm (range -4.8 to 3.0 mm) 
longitudinally, and -0.4 ± 1.5 mm (range -4.0 to 2.0 mm) 
laterally. 
Conclusions: There was no tumour displaced outside the PTV 
even during relatively slow SBRT delivery in all our lung cancer 
patients treated with SBRT without any customized 
immobilization. For our cohort of patients, the PTV margin (5 
mm) used was consistent with the measured residual intra-
fraction motion, also reported in other studies. This experience 
goes along with the growing trend in frameless, free-breathing 
SBRT for lung tumours. 
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Purpose: Obtaining a proper specimen for diagnostic pathology 
and genetic analysis can be challenging in some patients. The 
purpose of this study was to examine the diagnostic yield for 
different specimen types submitted for epidermal growth factor 
receptor (EGFR) mutation testing in patients with metastatic 
non-small cell lung cancer (NSCLC). 
Methods and Materials: A multicentre retrospective study was 
conducted of patients with a pathologic diagnosis of metastatic, 
non-squamous, NSCLC for the period 2010 to 2012. Patients were 
identified using a provincial cancer registry. Data was collected 
on patient characteristics, biopsy characteristics, and diagnostic 
outcome. All EGFR testing was done at a central lab for exon 19 
deletions and exon 21 mutations. 
Results: For 1499 patients, the pathologic diagnosis was 
determined from histology in 945 and cytology in 554. Six 
hundred twenty-seven (41.8%) of these patients had EGFR 
mutation testing. Mutation testing was requested in a higher 
proportion of patients with histology compared to those with 
cytology, 48.6% (459/945) versus 30.3% (168/554), respectively 
(p < 0.001). In patients with histology the diagnostic yield was 
88.2% (19.8% EGFR+; 68.4% EGFR wild type (WT); 11.8% non-
diagnostic). In patients with cytology the diagnostic yield was 
82.1% (17.9% EGFR+; 64.3% EGFR WT; 17.9% non-diagnostic). 
There was no statistically significant difference in diagnostic 
yield (p = 0.063) or mutation rates (p = 0.86) between the two 
specimen types. The histology and cytology cohorts were no 
different for age (p = 0.10), ECOG performance status (p = 0.39), 
and gender (p = 0.24). By location, specimens were obtained 
from the primary tumour in 317 (50.6%), thoracic lymph node in 
87 (13.9%), metastatic site in 158 (25.2%), and pleura/pleural 
fluid in 65 (10.4%). The diagnostic yields from these sites were 
84%, 87%, 91%, and 97%, respectively. 
Conclusions: For EGFR mutation testing, oncologists should not 
feel limited by biopsy site or specimen type. Cytology is 
sufficient for testing in most patients, and the diagnostic yield is 
comparable to histology. 
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Purpose: Miliary metastases arise from widespread 
hematogenous disease dissemination and are characterized by 
metastatic nodules that are diffuse, innumerable and small. The 
purpose of this study was to examine the incidence, prognostic 
significance, and impact of epidermal growth factor receptor 
(EGFR) mutations for miliary metastases from non-small cell lung 
cancer (NSCLC). 
Methods and Materials: Patients were identified from a 
Provincial cancer registry (British Columbia, Canada) for the 
period 2010-2012. Inclusion criteria were Stage IV NSCLC at 
initial presentation and conclusive EGFR mutation testing (for 
exons 19 and 21). Miliary metastases for each organ site were 
objectively defined as > 15 metastatic nodules of < 1 cm 
diameter size involving more than one organ lobe and bilaterally 
distributed. The primary endpoint was the association between 
EGFR mutations and miliary lung, brain, and liver metastases. 
The significance of EGFR mutation status and miliary metastases 
on survival were assessed using the Cox proportional hazards 
model. 
Results: For 543 patients, 422 (77.7%) were EGFR wild type (WT) 
and 121 (22.3%) EGFR mutation positive (EGFR+). Six (1.1%) 
patients had miliary brain metastases: two (0.5%) EGFR WT and 
four (3.3%) EGFR+ (exon 19 = 4; exon 21 = 0). Patients with an 
exon 19 mutation had a significantly higher incidence of miliary 
brain metastases compared to EGFR WT (p = 0.005). Twenty-nine 
(5.3%) patients had miliary lung metastases: 15 (3.6%) EGFR WT 
and 14 (11.6%) EGFR+ (exon 19 = 8; exon 21 = 6). Patients with 
EGFR+ status had a significantly higher incidence of miliary lung 
metastases compared to EGFR WT (p = 0.002). There was no 
difference in miliary lung metastases between exon subtypes (p 
= 0.78). Two (0.4%) patients had miliary liver metastases: two 
(0.5%) EGFR WT and none EGFR+. In multivariate analysis (MVA), 
miliary (versus non-miliary) brain (p = 0.47) and lung (p = 0.64) 
metastases were not significant factors for survival. EGFR+ status 
was significant for longer survival (p = 0.001) in MVA. 
Conclusions: Mutations in EGFR predispose to miliary brain and 
lung metastases. The survival outcome of patients with military 
brain and lung metastases is not adverse compared to non-
miliary metastases. 
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Purpose:  One of the purported advantages of SABR as an 
alternative treatment option to surgery for early-stage non-small 
cell lung cancer (ES-NSCLC) is health-related quality of life 
(HRQOL). The purpose of this study is to 1) perform a systematic 
review of HRQOL following SABR for ES-NSCLC and 2) to describe 
HRQOL and indirect costing outcomes from the ROSEL 
randomized trial comparing surgery and SABR for ES-NSCLC. 
Methods and Materials:  In ROSEL, 22 patients with ES-NSCLC 
were randomized to SABR or surgery before the trial closed due 
to poor accrual. HRQOL was evaluated at baseline, and then 
three, six, 12, 18, and 24 months post-treatment using the 30 
